Surrozen Inc (SRZN) — Titan Protect Analysis

SRZN

Surrozen Inc

Healthcare · ·

$21.52

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$282M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.10

Based on estimated future earnings — lower means cheaper

Rev Growth

+408.6%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$43.00

+100% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Surrozen Inc

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to

https://www.surrozen.com

Country: United States Employees: 44 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.889

Good returns relative to risk taken

Kelly Fraction

0.0667

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.797

Acceptable balance between returns and drawdown risk

Annual Return

49.2%

Historical annualised return based on price data

Max Drawdown

-61.8%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.59

Less volatile than the market — more defensive

52W High

$35.00

39% below the year high

52W Low

$8.00

169% above the year low

Avg Volume

107,531

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-36.59

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-209.1%

Profit from core operations before interest and tax

Free Cash Flow

$-26,107,124

Negative — the business is spending more than it generates

Revenue (TTM)

$7M

Total revenue over the last 12 months

Net Income

$-342,560,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$44.00

Target Median

$43.00

Target Low

$40.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go